# Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda

> **NCT00489658** · PHASE2,PHASE3 · TERMINATED · sponsor: **Epicentre** · enrollment: 31 (actual)

## Conditions studied

- Trypanosomiasis, African

## Interventions

- **DRUG:** Eflornithine plus Nifurtimox combination therapy

## Key facts

- **NCT ID:** NCT00489658
- **Lead sponsor:** Epicentre
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Because of unexpectedly reduced disease prevalence in the study area, a pragmatic decision was taken to terminate recruitment in March 2003.
- **Last updated:** 2007-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00489658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00489658, "Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00489658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*